PubPredict: Prediction of progression and survival in oncology leveraging publications and early efficacy data.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 963, doi. 10.1002/pst.2321
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2023 AND VI 22 AND IP 5
Results: 14
1
2
Determining the minimum duration of treatment in tuberculosis: An order restricted non‐inferiority trial design.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 938, doi. 10.1002/pst.2320
- By:
- Publication type:
- Article
3
Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 921, doi. 10.1002/pst.2319
- By:
- Publication type:
- Article
4
Alone, together: On the benefits of Bayesian borrowing in a meta‐analytic setting.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 903, doi. 10.1002/pst.2318
- By:
- Publication type:
- Article
5
Variance estimation of the risk difference when using propensity‐score matching and weighting with time‐to‐event outcomes.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 880, doi. 10.1002/pst.2317
- By:
- Publication type:
- Article
6
Replenishing the pipeline: A quantitative approach to optimising the sourcing of new projects.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 861, doi. 10.1002/pst.2316
- By:
- Publication type:
- Article
7
Adaptively leveraging external data with robust meta‐analytical‐predictive prior using empirical Bayes.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 846, doi. 10.1002/pst.2315
- By:
- Publication type:
- Article
8
How to avoid concerns with the interpretation of two primary endpoints if significant superiority in one is sufficient for formal proof of efficacy.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 836, doi. 10.1002/pst.2314
- By:
- Publication type:
- Article
9
Bayesian borrowing from historical control data in a vaccine efficacy trial.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 815, doi. 10.1002/pst.2313
- By:
- Publication type:
- Article
10
A comparative study of adaptive trial designs for dose optimization.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 797, doi. 10.1002/pst.2306
- By:
- Publication type:
- Article
11
Stability analysis using mixed models: A critique of tolerance interval methods and a probabilistic solution.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 784, doi. 10.1002/pst.2305
- By:
- Publication type:
- Article
12
Time‐to‐event calibration‐free odds design: A robust efficient design for phase I trials with late‐onset outcomes.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 773, doi. 10.1002/pst.2304
- By:
- Publication type:
- Article
13
Improved inference for MCP‐Mod approach using time‐to‐event endpoints with small sample sizes.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 760, doi. 10.1002/pst.2303
- By:
- Publication type:
- Article
14
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 5, p. 757, doi. 10.1002/pst.2239
- Publication type:
- Article